619 related articles for article (PubMed ID: 29338455)
21. [MOLECULAR PATHOLOGY OF MENINGIOMAS].
Murnyák B; Csonka T; Hortobágyi T
Ideggyogy Sz; 2015 Sep; 68(9-10):292-300. PubMed ID: 26665490
[TBL] [Abstract][Full Text] [Related]
22. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
[TBL] [Abstract][Full Text] [Related]
23. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.
Aizer AA; Abedalthagafi M; Bi WL; Horvath MC; Arvold ND; Al-Mefty O; Lee EQ; Nayak L; Rinne ML; Norden AD; Reardon DA; Wen PY; Ligon KL; Ligon AH; Beroukhim R; Dunn IF; Santagata S; Alexander BM
Neuro Oncol; 2016 Feb; 18(2):269-74. PubMed ID: 26323607
[TBL] [Abstract][Full Text] [Related]
24. Skull base atypical meningioma: long term surgical outcome and prognostic factors.
Wang YC; Chuang CC; Wei KC; Hsu YH; Hsu PW; Lee ST; Wu CT; Tseng CK; Wang CC; Chen YL; Jung SM; Chen PY
Clin Neurol Neurosurg; 2015 Jan; 128():112-6. PubMed ID: 25486076
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery.
Kim M; Lee DH; Kim Rn HJ; Cho YH; Kim JH; Kwon DH
Clin Neurol Neurosurg; 2017 Feb; 153():93-101. PubMed ID: 28081463
[TBL] [Abstract][Full Text] [Related]
26. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract][Full Text] [Related]
27. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
Yang SY; Park CK; Park SH; Kim DG; Chung YS; Jung HW
J Neurol Neurosurg Psychiatry; 2008 May; 79(5):574-80. PubMed ID: 17766430
[TBL] [Abstract][Full Text] [Related]
28. Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?
Góes P; Santos BFO; Suzuki FS; Salles D; Stávale JN; Cavalheiro S; de Paiva Neto MA
J Neurooncol; 2018 Apr; 137(2):331-336. PubMed ID: 29270884
[TBL] [Abstract][Full Text] [Related]
29. Meningioma: current updates on genetics, classification, and mouse modeling.
Szulzewsky F; Thirimanne HN; Holland EC
Ups J Med Sci; 2024; 129():. PubMed ID: 38571886
[TBL] [Abstract][Full Text] [Related]
30. [Problems in treatment for meningiomas].
Takahashi J; Hashimoto N
Nihon Rinsho; 2005 Sep; 63 Suppl 9():303-9. PubMed ID: 16201539
[No Abstract] [Full Text] [Related]
31. The Natural History and Treatment of Meningiomas: An Update.
Nyalundja AD; Mugisha F; Karekezi C
Semin Neurol; 2024 Feb; 44(1):1-15. PubMed ID: 38052237
[TBL] [Abstract][Full Text] [Related]
32. Intracranial Clear Cell Meningiomas: Study on Clinical Features and Predictors of Recurrence.
Zhang H; Ma L; Wang YB; Shu C; Kuang W; Huang YA; Dong LQ; Cheng GG
World Neurosurg; 2017 Jan; 97():693-700.e11. PubMed ID: 27744084
[TBL] [Abstract][Full Text] [Related]
33. Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases.
Cornelius JF; Slotty PJ; Steiger HJ; Hänggi D; Polivka M; George B
Acta Neurochir (Wien); 2013 Mar; 155(3):407-13. PubMed ID: 23318687
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.
Sioka C; Kyritsis AP
J Neurooncol; 2009 Mar; 92(1):1-6. PubMed ID: 19023520
[TBL] [Abstract][Full Text] [Related]
35. Genomic landscape of intracranial meningiomas.
Bi WL; Abedalthagafi M; Horowitz P; Agarwalla PK; Mei Y; Aizer AA; Brewster R; Dunn GP; Al-Mefty O; Alexander BM; Santagata S; Beroukhim R; Dunn IF
J Neurosurg; 2016 Sep; 125(3):525-35. PubMed ID: 26771848
[TBL] [Abstract][Full Text] [Related]
36. Predictors of Treatment Response and Survival Outcomes in Meningioma Recurrence with Atypical or Anaplastic Histology.
Chohan MO; Ryan CT; Singh R; Lanning RM; Reiner AS; Rosenblum MK; Tabar V; Gutin PH
Neurosurgery; 2018 Jun; 82(6):824-832. PubMed ID: 28645194
[TBL] [Abstract][Full Text] [Related]
37. Multimodal Management of Metastatic Malignant Meningiomas: The Role of Radiosurgery in Long-Term Local Control.
Attuati L; Zaed I; Morselli C; Pecchioli G; Fornari M; Picozzi P
World Neurosurg; 2019 Aug; 128():562-572. PubMed ID: 31102770
[TBL] [Abstract][Full Text] [Related]
38. Stereotactic radiosurgery and stereotactic radiotherapy in the treatment of skull base meningiomas.
McGregor JM; Sarkar A
Otolaryngol Clin North Am; 2009 Aug; 42(4):677-88. PubMed ID: 19751872
[TBL] [Abstract][Full Text] [Related]
39. Atypical meningiomas.
Chen R; Aghi MK
Handb Clin Neurol; 2020; 170():233-244. PubMed ID: 32586495
[TBL] [Abstract][Full Text] [Related]
40. Interinstitutional variance of postoperative radiotherapy and follow up for meningiomas in Germany: impact of changes of the WHO classification.
Simon M; Boström J; Koch P; Schramm J
J Neurol Neurosurg Psychiatry; 2006 Jun; 77(6):767-73. PubMed ID: 16306156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
